weeks in Medical Technology

BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients

MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with BARACLUDE(R) (entecavir) resulted in greater long-term viral l...

CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients

Data also showed differences in gastrointestinal and lipid effects between REYATAZ/ritonavir and lopinavir/ritonavir among study population PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced results from the CASTLE study, in which 300...

Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks

- MAXIMA findings in The Lancet affirm the maintenance of hemoglobin levels with less frequent dosing - NUTLEY, N.J., Oct. 19 /PRNewswire/ -- A pivotal study published today in The Lancet has shown that dialysis patients were effectively switched from frequently-dosed anemia...

Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial

In Difficult-to-Immunize Population, Demonstrates Superior Long-Term Seroprotection Compared to Conventional Vaccine BERKELEY, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX ) announced today that the seroprotection of HEPLISAV at 50 wee...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

ZURICH, July 16 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received a second orphan drug designation in the US only weeks after a first designation was granted. The recent designation relates to Burkholderia cepacia pathogens...

Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks

- Roche progresses R1626 into phase IIb study, called POLI 1 - BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa...

Study Presented at ACC Shows Treatment With ISIS 301012 Added to Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C Levels of Less Than 70 mg/dL

* ISIS 301012 coadministered with statins for only five weeks at 400 mg/week lowered LDL-C 47% beyond the levels achieved with statins alone, with similarly favorable effects on other atherogenic lipids NEW ORLEANS and CARLSBAD, Calif., March 26, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals...

Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients

WASHINGTON, May 21, 2007/PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced new data from study ETV-079, which showed that treatment with Baraclude (entecavir) demonstrated greater viral load reduction than adefovir at 48 weeks -- a result that was also seen at weeks...

Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial

~ Valopicitabine achieved both primary and secondary endpoints of study; no negative drug-drug interaction was observed between valopicitabine and ribavirin ~ CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. today announced results from a phase II study design...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improve...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

EXCLAIM is the First International Study to Show That Extended Thromboprophylaxis Reduces VTE Risk in Acutely-ill Medical Patients With a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced today the results of the EXCLAIM (EXtended CLinical prophy...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... determine E fficacy) enrolled 1,183 patients globally. Patients were randomized to receive either 6.0 mg/kg of Vectibix and FOLFOX4 once every two weeks (Q2W) or FOLFOX4 alone Q2W. The primary endpoint of the study is progression-free survival by KRAS status and secondary endpoints include overall su...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...t the study met its primary endpoint with a 25% reduction in LDL-C after 26 weeks of treatment with mipomersen versus 3% for placebo and all of its secondary... The study met its primary endpoint, with a 25% reduction in LDL-C after 26 weeks of treatment, vs. 3% for placebo (p<0.001). The study also met each of ...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

...onth treatment period. Patients were on average 65 years old (54-84) and had an average lumbar spine BMD T-score of -2.93. All patients underwent four weeks of pretreatment with standard regional supplementation requirements for osteoporosis of not less than 400 IU per day of Vitamin D and not less than 50...

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone

...ring facility in Rockville, MD. This milestone was accomplished in only 11 weeks after receiving the gene sequence for the H1N1 strain from the U.S. Centers...ur ability to construct and produce GMP-quality influenza vaccine within 12 weeks under real pandemic conditions is an important and successful test of our V...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...a. Patients enrolled in this event-driven study were randomized in a one-to-one ratio to receive either 120 mg of denosumab subcutaneously every four weeks (Q4W) or Zometa administered intravenously at a dose of 4 mg single, 15 minute infusion every four weeks. In clinical trials thus far to test ...

British Woman Celebrates a Year of Living Cancer-Free

...ed by the type of leukemia she had -- confirmed that the TaNK cells were attacking her cancer. Ms. Scott had to return to the hospital for five weeks because her neutrophils, a type of white blood cell, were dangerously low -- a consequence, she thinks, of years of chemotherapy. Since her discharge,...

Treatment Shows Excellent Results for Providence Tarzana Patients Following Cardiac Arrest

... TARZANA, Calif., July 28 /PRNewswire-USNewswire/ -- Less than two weeks after instituting new therapeutic hypothermia treatment for heart attack patients, Providence Tarzana Medical Center has applied the body-cooling trea...

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

...ks. Both expert visual grading analysis and objective computer image analysis of high-resolution digital images of the subjects before and after three weeks of treatment, confirmed the effects were significant and noticeable. Dryness reversed in one week (after switching from regular body wash) ...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... Use ASMANEX as directed by your health care provider, since its ability to work in your lungs depends on regular use. Maximum benefit may take 1 to 2 weeks or longer. If your asthma symptoms do not improve, or get worse, contact your health care provider. The most common side effects with ASMANE...

Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler

... the body over time and require repeat injections to maintain wrinkle correction. A skin test is required prior to treatment or approximately four (4) weeks ahead of time, to ensure a patient is not allergic to the collagen or anesthetic in Artefill. Artefill is only offered by a select group of ...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

...ntihypertensive effect of Tekturna HCT were largely manifested within 1 week. The maximum antihypertensive effect was generally attained after about 4 weeks of therapy. About Tekturna and Tekturna HCT TEKTURNA and TEKTURNA HCT are prescription medications for adults used to treat high ...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

...ay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 20088902. An archived webcast will also be available for two weeks after the call on the Idenix website. About Idenix Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopha...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

...blood sugar over three months, of 1.5 percentage points from baseline, compared to a reduction of 1.3 percentage points for Lantus after completing 26 weeks of treatment. At the end of the study, patients treated with exenatide once weekly achieved a mean A1C of 6.8 percent compared with a mean A1C of 7.0 ...

New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed

...dy's primary endpoint was virologic response at 48 weeks of treatment, with response defined as a viral loa...utive visits prior to week 48 (i.e. suppression at weeks 24 and 36) and without subsequent rebound or chang...V/r. The rate of serious adverse events seen at 48 weeks in patients was 9.6 percent in the nevirapine grou...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...g per day or less during the last 12 weeks of study (p=0.053 for 10 mg/kg and p...on of therapy in the two studies is different - 52 weeks for BLISS-52 and 76 weeks for BLISS-76. The data from BLISS-76 will be analy...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

...ated animals developed HI antibody levels considered to be protective. These responses were boosted approximately 8-fold by a second dose given three weeks later. Responses measured by ELISA and ELISPOT assays, which assess antibody and T cell responses, respectively, mirrored the HI responses. The desi...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

... patients (47-48 per treatment arm). Following 24 weeks of treatment, a formal interim analysis was conduc...ho continued on vicriviroc at the completion of 48 weeks of treatment in an open-label extension for each study. Patients received vicriviroc for up to 216 weeks of total treatment duration as part of an optimize...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

...atio (INR) of 2.0-3.0 for 12 weeks. The INR was determined weekly for four weeks and every two weeks thereafter. Investigators, sponsors and study subjects were blinded to the...

GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas

...d an incremental test to exhaustion prior to supplementation and after four weeks of supplementation. Key study findings demonstrate significant mean increa....6%). The study followed 50 college-aged males over the course of four weeks who were randomized into one of three groups - a. placebo (microcrystalline...

Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows

...eing noted. "In our study, the largest of skeletally immature patients to evaluate independent risk factors, a delay in treatment of more than 12 weeks had about a four-fold increase in irreparable medial meniscus tears, an 11-fold increase in lateral compartment chondral injuries and a three-fold i...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

... Use ASMANEX as directed by your health care provider, since its ability to work in your lungs depends on regular use. Maximum benefit may take 1 to 2 weeks or longer. If your asthma symptoms do not improve, or get worse, contact your health care provider. The most common side effects with ASMANEX in ...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

...o-one ratio to receive either 120 mg of denosumab subcutaneously every four weeks (Q4W) or Zometa administered intravenously at a dose of 4 mg single, 15 minute infusion every four weeks as per the labeled use. In clinical trials testing new medications fo...

June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates

... possible allergies. Poison ivy and poison oak: Contact with these plants causes red, swollen skin, blisters and severe itching within days or weeks of exposure. These plants produce an oily substance called urushiol, which causes an allergic reaction in most people. Urushiol can stick to almost an...

Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets

...r of bowel movements) in approximately three out of four of patients by six weeks and decreased rectal bleeding for approximately 80 percent of patients by s...tal daily dose of 4.8 g. The safety and effectiveness of Asacol HD beyond 6 weeks has not been established. In clinical trials, Asacol and Asacol HD wer...

Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis

...ut also can be caused by other viruses, such as enterovirus. There is no specific treatment for adenoviral conjunctivitis, which can take up to three weeks or longer to clear on its own. Bacterial conjunctivitis is caused by a variety of bacteria and is largely treated with topically applied antibiotic e...

MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants

...ncytial virus (RSV) among preterm infants 32-to-35 weeks gestational age (GA) in outpatient settings during...alf of under-represented and under-served 32-to-35 weeks (GA) preterm infants. This observational, p...tudy population will include infants born 32-to-35 weeks (GA) who do not receive RSV prophylaxis during the...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

... pooled analysis indicating that most adverse events begin within the first weeks of treatment but after six weeks, no relevant difference was found between ...reatment related adverse events were mild or moderate in intensity. After 6 weeks of treatment, there were no observed differences in the incidence of side e...

Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237

...A237 for a 52-week period. The primary endpoint of the study will be the change from baseline in FEV1 (forced expiratory volume in one second) over 12 weeks of treatment. A number of secondary endpoints will also be evaluated. NVA237 was licensed to Novartis in April 2005 by Sosei and its co-develop...

Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis

...ow often and the specific combination of food and beverages ingested. Give yourself plenty of time to discover your ideal diet. It may require several weeks of trial and error. Eat a healthy, varied, balanced diet -- most patients can do this if they work to identify problem items first. ...